# PRIMARY ADRENAL INSUFFICIENCY IN YOUNG BOYS IS A RED FLAG FOR ALD

- Adrenoleukodystrophy (ALD) is a frequent cause of primary adrenal insufficiency in young boys who
  present in the absence of adrenal antibodies<sup>1</sup>
- ALD is a rare X-linked disorder resulting from mutations in the *ABCD1* gene.<sup>2</sup> The early symptoms of ALD are similar to other medical conditions, making diagnosis challenging<sup>3</sup>
- ALD may develop into cerebral ALD, a severe form of the disease<sup>2</sup>
- Cerebral ALD leads to severe neurodegeneration and often death within a decade of diagnosis<sup>1,4,5</sup>

### SOME FACTS ABOUT ALD

- Roughly 80% of young boys diagnosed with ALD also had some form of adrenal insufficiency<sup>6</sup>
- ALD occurs in about 1 in 21,000 males<sup>7</sup>
- Causes impaired peroxisomal  $\beta$ -oxidation of very long chain fatty acids (VLCFA), resulting in accumulation of VLCFA in plasma and tissues<sup>8</sup>
- Clinical manifestation of ALD varies widely, even among members of the same family.<sup>7</sup> Patients may exhibit a variety of phenotypes, such as adrenal insufficiency, adrenomyeloneuroapthy (AMN) affecting the spinal cord and peripheral nervous system in adults, or the rapidly progressive cerebral form (cerebral ALD).<sup>8</sup>
- Early symptoms are variable and non-specific but may include behavioral or learning issues and audiovisual impairment<sup>4,8</sup>
- About 35-40% of boys with ALD will develop cerebral ALD which leads to progressive behavioral, cognitive, and neurologic deficits and, in most patients, total disability and death within a decade of diagnosis<sup>4,5</sup>
- Symptoms of cerebral ALD generally present between the ages of 3 to  $12^{1.5}$

#### MEASUREMENT OF VLCFA LEVELS IN PLASMA MAY HELP DIAGNOSE ALD

- Increased plasma levels of VLCFA are suggestive of ALD<sup>4</sup>
- Boys with primary adrenal insufficiency who are negative for 21-hydroxylase antibodies should be assessed for ALD by measuring VLCFA levels in plasma<sup>9</sup>
- If you suspect ALD, refer the patient to a pediatric neurologist<sup>3</sup>

#### EARLY DIAGNOSIS OF ALD COULD SAVE A LIFE

- Cerebral ALD can be treated with hematopoietic stem cell transplantation if the disease is diagnosed in its early stages<sup>2,3</sup>
- Early diagnosis gives boys with cerebral ALD the best chance at positive long-term outcomes<sup>3,10</sup>

## WHEN YOU SEE ANTIBODY-NEGATIVE PRIMARY ADRENAL INSUFFICIENCY—CHECK FOR ALD

References: 1. Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. *Orphanet J Rare Dis.* 2012;7:51. 2. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. *Blood.* 2011;118(7):1971-1978. 3. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. *Nat Clin Pract Neurol.* 2007;3(3):140-151. 4. Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. *Curr Neurol Neurosci Rep.* 2014;14(10):486. 5. Mahmood A, Dubey P, Moser HW, Moser A. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. *Pediatr Transplant.* 2005;9 (suppl 7):55-62. 6. Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. *J Pediatr.* 2005;146(4):528-532. 7. Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. *Ann Neurol.* 2001;49(4):512-517. 8. Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy – neuroendocrine pathogenesis and redefinition of natural history. *Nat Rev Endocrinol.* 2016;12(10):606-615. 9. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2016;101(2):364-389. 10. Raymond GV, Aubourg P, Paker A, et al. Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2019;25(3):538-548.

bluebird bio would like to thank the various patient organizations who provided invaluable time and feedback on the concept of this educational initiative. bluebird bio and the bluebird bio logo are the trademarks of bluebird bio, Inc. © 2021 bluebird bio, Inc. All rights reserved. ALD-US-00132 08/21

